Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset

NCT05507645 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT05507645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2022
Completion date
June 17, 2024
Enrollment
1,446 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke, mild, thrombosis